![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Mark DeBenedette, Alicia Gamble, Marcus Norris, Joe Horvatinovich & Charles A. Nicolette. (2023) A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma. Human Vaccines & Immunotherapeutics 19:2.
Read now
Read now
Sandy Giuliano, Mélanie Guyot, Renaud Grépin & Gilles Pagès. (2014) The ELR+CXCL chemokines and their receptors CXCR1/CXCR2. OncoImmunology 3:4.
Read now
Read now
Shannon N. Westin & Russell R. Broaddus. (2012) Personalized therapy in endometrial cancer: Challenges and opportunities. Cancer Biology & Therapy 13:1, pages 1-13.
Read now
Read now
Timo T Purmonen. (2011) Cost–effectiveness of sunitinib in metastatic renal cell carcinoma. Expert Review of Pharmacoeconomics & Outcomes Research 11:4, pages 383-393.
Read now
Read now
Filippo Spreafico, Paola Collini, Monica Terenziani, Alfonso Marchianò & Luigi Piva. (2010) Renal cell carcinoma in children and adolescents. Expert Review of Anticancer Therapy 10:12, pages 1967-1978.
Read now
Read now
Articles from other publishers (15)
Xavier L. Baldwin, Philip M. Spanheimer & Stephanie Downs-Canner. (2023) A Review of Immune Checkpoint Blockade for the General Surgeon. Journal of Surgical Research 281, pages 289-298.
Crossref
Crossref
Sandra Donnini, Arianna Filippelli, Valerio Ciccone, Andrea Spini, Emma Ristori, Marina Ziche & Lucia Morbidelli. 2022. Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy. Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy
29
66
.
Maeva Dufies, Sandy Giuliano, Damien Ambrosetti, Audrey Claren, Papa Diogop Ndiaye, Michalis Mastri, Walid Moghrabi, Lindsay S. Cooley, Marc Ettaiche, Emmanuel Chamorey, Julien Parola, Valerie Vial, Marilena Lupu-Plesu, Jean Christophe Bernhard, Alain Ravaud, Delphine Borchiellini, Jean-Marc Ferrero, Andréas Bikfalvi, John M. Ebos, Khalid Saad Khabar, Renaud Grépin & Gilles Pagès. (2017) Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas. Cancer Research 77:5, pages 1212-1226.
Crossref
Crossref
Deepa Anand & Carmen P. Escalante. (2015) Ongoing Screening and Treatment to Potentially Reduce Tyrosine Kinase Inhibitor-Related Fatigue in Renal Cell Carcinoma. Journal of Pain and Symptom Management 50:1, pages 108-117.
Crossref
Crossref
Hideaki Miyake, Akira Miyazaki, Ken-ichi Harada & Masato Fujisawa. (2014) Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan. Medical Oncology 31:6.
Crossref
Crossref
Kelly L. Vallance & Jeffrey S. Dome. 2014. Renal Disease in Cancer Patients. Renal Disease in Cancer Patients
129
159
.
Angheliki Nomikos & Grant Stenhouse. (2013) Pathology of urinary tract tumours. Surgery (Oxford) 31:10, pages 504-508.
Crossref
Crossref
Matthew J. Brauer, Guanglei Zhuang, Maike Schmidt, Jenny Yao, Xiumin Wu, Joshua S. Kaminker, Stefanie S. Jurinka, Ganesh Kolumam, Alicia S. Chung, Adrian Jubb, Zora Modrusan, Tomoko Ozawa, C. David James, Heidi Phillips, Benjamin Haley, Rachel N.W. Tam, Anne C. Clermont, Jason H. Cheng, Sherry X. Yang, Sandra M. Swain, Daniel Chen, Stefan J. Scherer, Hartmut Koeppen, Ru-Fang Yeh, Peng Yue, Jean-Philippe Stephan, Priti Hegde, Napoleone Ferrara, Mallika Singh & Carlos Bais. (2013)
Identification and Analysis of
In Vivo
VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
. Clinical Cancer Research 19:13, pages 3681-3692.
Crossref
Crossref
Muhammad A. Siraj, Christophe Pichon, Aurelian Radu & Nicolae Ghinea. (2012) Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib. Journal of Cellular and Molecular Medicine 16:9, pages 2010-2016.
Crossref
Crossref
Manuela Schmidinger & Jutta Bergler-Klein. (2012) Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma. International Journal of Urology 19:9, pages 796-804.
Crossref
Crossref
Timothy V. Johnson, Jennifer DeLong & Viraj A. Master. (2012) C-reactive protein: A clinically useful biomarker in renal cell carcinoma. Journal of the American Academy of Physician Assistants 25:1, pages 45-47.
Crossref
Crossref
Filippo Spreafico & Norbert Graf. 2012. Rare Tumors In Children and Adolescents. Rare Tumors In Children and Adolescents
403
419
.
Anikó Maráz. (2011) Novelties of treatment in advanced renal-cell cancer. Orvosi Hetilap 152:17, pages 655-662.
Crossref
Crossref
Richard Oparka & Grant Stenhouse. (2010) Pathology of urinary tract tumours. Surgery (Oxford) 28:12, pages 584-588.
Crossref
Crossref
Timothy V. Johnson, Andrew N. Young, Adeboye O. Osunkoya & Viraj A. Master. (2012) C-Reactive Protein as a Clinically Useful Biomarker of Metastasis of Renal Cell Carcinoma. Molecular Diagnosis & Therapy 14:3, pages 191-193.
Crossref
Crossref